- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04745195
Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium (COMPETE)
Diagnostic and Risk Criteria for Complement Defects in Thrombotic Microangiopathy and Amplifying Conditions, Such as Severe Hypertension: The COMPETE Study.
Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions. Dysregulation of the alternative pathway of complement may be the etiological factor and this type of TMA is classified, according to the current nomenclature, as primary atypical hemolytic uremic syndrome (HUS). Half the patients with primary atypical HUS present with rare variants in complement genes, although coexisting conditions are often needed for the TMA to become manifest. In patients with secondary atypical HUS, certain coexisting conditions appear to drive the disease and treatment should target the underlying condition to remit the TMA.
Recently, the investigators demonstrated, by using a novel in-house developed functional endothelial cell-based test, that complement dysregulation and overactivation is the dominant cause of disease and its sequelae in a subset of patients with secondary atypical HUS, having impact on treatment and prognosis. The investigators did first prove this concept in patients presenting with TMA and hypertensive emergency. A prospective study is needed to further corroborate these findings along the spectrum of TMA. The investigators hypothesize that their functional endothelial cell-based test, the so-called "HMEC" test, can better categorizes the TMA into different groups with potential therapeutic and prognostic implications. Thus, paving the road to the ultimate goal of precision medicine.
Study Overview
Status
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Pieter van Paassen, MD, PhD
- Phone Number: +31(0)433871198
- Email: p.vanpaassen@maastrichtuniversity.nl
Study Contact Backup
- Name: Sjoerd Timmermans, MD
- Phone Number: +31(0)433871198
- Email: sjoerd.timmermans@mumc.nl
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229HX
- Recruiting
- Maastricht University Medical Center
-
Contact:
- Pieter van Paassen, MD, PhD
- Phone Number: +31(0)433871198
- Email: p.vanpaassen@maastrichtuniversity.nl
-
Contact:
- Sjoerd Timmermans, MD
- Phone Number: +31(0)433871198
- Email: sjoerd.timmermans@mumc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males or females at least 18 years of age;
- Have acute kidney injury, defined as estimated GFR <45 mL/min/1.73m2;
- Have documented TMA either on peripheral blood, defined as Coombs negative microangiopathic hemolytic anemia (hematocrit <30%, hemoglobin <6.5 mmol/L [<10 g/dL], lactate dehydrogenase >500 U/L, and either schistocytes on peripheral blood smear or undetectable haptoglobin), and platelets <150,000 per µL, or kidney biopsy;
Have primary atypical HUS or a coexisting condition linked to complement dysregulation:
- Hypertensive emergency, defined as SBP/DBP of >180/120 mmHg and impending organ damage secondary to hypertension (at least one of the following: neurologic disease, hypertensive retinopathy grade III and/or IV, left ventricular hypertrophy); OR
- Pregnancy, including 12 weeks postpartum; OR
- Kidney donor recipient; OR
- Systemic auto-immune disease associated with TMA, including systemic sclerosis, systemic lupus erythematosus, anti-phospholipid syndrome;
- Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.
Exclusion Criteria:
- Have secondary causes of hypertensive emergency, including renovascular hypertension, Cushing syndrome, aldosteronism, pheochromocytoma, thyroid disease;
- Have a nephropathy not related to thrombosis on kidney biopsy;
- Have ADAMTS13 deficiency, defined as ADAMTS13 activity <10%;
- Have a positive stool culture for Shiga toxin producing bacteria;
- Have positive serologic test for viral infections, including HIV and CMV;
- Have a history of malignant disease, excluding non-melanoma skin cancer;
- Have a history of bone marrow or solid organ transplantation, excluding kidney transplantation;
- Received at least one of the following agents: chemotherapeutics, sirolimus, anti-VEGF agents;
- Have a history of recent past exposure to illicit drug(s).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Complement-mediated thrombotic microangiopathy
|
Thrombotic microangiopathty with normal complement regulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The prevalence of complement-mediated TMA along the spectrum of TMA
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The diagnostic performance of the "HMEC" test for the diagnosis of complement-mediated TMA
Time Frame: 1 year
|
1 year
|
|
The dynamics of ex vivo C5b9 formation on the endothelium during the course of TMA
Time Frame: every month for up to 1 year
|
every month for up to 1 year
|
|
The dynamics of ex vivo C5b9 formation on the endothelium as compared to routine complement measures during the course of TMA
Time Frame: every month for up to 1 year
|
every month for up to 1 year
|
|
Composite kidney endpoint: 50% eGFR decline, chronic kidney disease stage G5, end-stage kidney disease
Time Frame: 1 year
|
The diagnostic and prognostic value of pathologic features and chronicity indices on kidney biopsy at the time of presentation
|
1 year
|
composite TMA endopoint: TMA recurrence, end-stage kidney disease
Time Frame: 1 year
|
The prognostic value of genetic variants in complement genes
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Kidney Diseases
- Urologic Diseases
- Disease
- Hematologic Diseases
- Anemia
- Thrombocytopenia
- Blood Platelet Disorders
- Anemia, Hemolytic
- Uremia
- Syndrome
- Vascular Diseases
- Thrombotic Microangiopathies
- Azotemia
- Hemolysis
- Hemolytic-Uremic Syndrome
- Atypical Hemolytic Uremic Syndrome
Other Study ID Numbers
- NL74928.068.20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombotic Microangiopathies
-
Peking University Third HospitalNot yet recruitingPregnancy-related Thrombotic Microangiopathies
-
The First Affiliated Hospital of Soochow UniversityRecruiting
-
University of California, San FranciscoCompleted
-
University of CologneUnknownThrombotic Microangiopathies
-
University Hospital, MontpellierRecruitingThrombotic Micro-angiopathyFrance
-
Omeros CorporationImpatients N.V. trading as myTomorrowsAvailableHematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
-
Hospices Civils de LyonRecruitingHematopoietic Stem Cell Transplantation-Associated Thrombotic MicroangiopathyFrance
-
Omeros CorporationRecruitingThrombotic Microangiopathies | Hematopoietic Stem Cell TransplantationUnited States, Germany, Israel, Netherlands, Spain
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingThrombotic Microangiopathies
-
AKARI TherapeuticsRecruitingThrombotic MicroangiopathiesUnited States, United Kingdom, Poland